Pharmafile Logo
Pharmafocus logo
Advanced Search

Dovato

Showing 3 posts of 3 posts found.

landing-hero-images1

Japan welcomes approval of ViiV’s Dovato for HIV-1

January 17, 2020
Medical Communications, Sales and Marketing Dovato, Japan, ViiV Healthcare, pharma

Japan’s Ministry of Health, Labour and Welfare (MHLW) has awarded marketing approval to ViiV Healthcare, a subsidiary of GSK, for …

News
1920px-hiv-budding-color

ViiV Healthcare’s two drug HIV therapy beats Gilead’s three drug treatment in Phase 3 trial

July 10, 2019
Research and Development AIDS, Dovato, GSK, Gilead, HIV, ViiV, pharma

Pfizer and GlaxoSmithKline’s HIV company, ViiV Healthcare, has said its two-drug combo Dovato (dolutegravir and lamuvidine) met its primary endpoint …

News
landing-hero-images1

ViiV’s Dovato approved in Europe as treatment option for HIV-1

July 3, 2019
Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024